Current status of iron overload and chelation with deferasirox

  title={Current status of iron overload and chelation with deferasirox},
  author={Ved Prakash Choudhry and Rahul Naithani},
  journal={The Indian Journal of Pediatrics},
A large number of complications in thalassemia major are due mainly to iron overload. Deferoxamine in iron-overloaded patients has established that chelation therapy, when given at an adequate dose, reduces iron-related complications. Parenteral administration and the daily nuisance of an infusion pump hinder the optimal compliance. Deferiprone is moderately effective oral iron chelator. Arthralgia and cytopenias constitute the main side effects. Deferasirox is a new orally effective iron… 

Formulation of oral iron chelator deferasirox in a new stable and suitable dosage form with optimum release parameters

Oral iron chelator, Deferasirox used in the treatment of β-thalessemia is designed and developed into a stable solid oral dispersion dosage form to deliver with optimum concentration of the drug at desired site at specific time comparable to the innovator product.

Effect of deferasirox therapy on serum ferritin level and its side effect in Iraqi thalassemia patients

Oral chelating agent deferasirox is well affordable with long-term treatment and the adverse effects are minimal with this medication; therefore optimum treatment is needed to produce the good clinical result and decrease or no adverse effects in a good acceptable dose.

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia

It is concluded that, silymarin in combination with Exjade can be safely used in the treatment of iron-loaded thalassemic patients as it showed good iron chelation with no sign of toxicity.

The Effect of Deferasirox on the Oxidative Stress and Inflammation in Iron Overloaded Beta-Thalassemic Patients

Deferasirox can play important role in controlling the oxidative stress and inflammation which are secondary to iron overload and is noticed from the significant decrease in the oxidative parameter (MDA), the inflammatory parameter (CRP), and the significant increase in the antioxidant (GSH).

Safety and efficacy of deferasirox in multitransfused Indian children with β‐thalassaemia major

Therapy with deferasirox is safe in paediatric patients with thalassaemia major, however, they should be carefully monitored for side‐effects.

Practice of iron chelation therapy for transfusion-dependent thalassemia in Southeast Asia

The scope of iron chelation practices including the types of chelators that are available in Southeast Asia are discussed, and issues relevant to the treatment of transfusion-dependent thalassemic patients in this region are explored.

Efficacy of Deferasirox in North Indian &bgr;-Thalassemia Major Patients: A Preliminary Report

Deferasirox (DFX) is a relatively safe oral iron chelator that can be used in Asian Indians, with gastrointestinal problems like diarrhea and abdominal pain as the most common side effects.

Effects Of Deferasirox Therapy On High Sensitivity C- Reactive Protein and Oxidative Stress Markers In Iron Overloaded, Beta-Thalassemic Patients

Iron chelation therapy with DFX was effective in decreasing MDA and hs-CRP and increasing the antioxidant markers (GSH) and TAC in iron overloaded blood transfused beta thalassemic patients, suggesting that DFX therapy can play important role in controlling oxidative stress and inflammation in these patients.

Efficacy and safety of deferasirox for reducing total body and cardiac iron in Thalassemia

Deferasirox monotherapy has a good safety profile and effectively chelates total body iron and is also a good myocardial iron chelator, more efficacious in moderate to severe cardiac iron overloaded patients.

Formulation Development and Evaluation of Deferasirox Dispersible Tablets

The present study treatment of iron storage disease is to remove from the body the excess iron that has accumulated by employing iron Chelators and Deferasirox dispersible tablets is indicated in for the treatment of chronic Iron overload.



Iron-chelating therapy and the treatment of thalassemia.

The toxicity of this agent mandates a careful evaluation of the balance between risk and benefit of deferiprone in patients with thalassemia, in most of whom long-term deferoxamine is safe and efficacious therapy.

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

Retrospective epidemiologic data suggest dramatic reductions in cardiac events and mortality in Italian subjects exposed to deferiprone compared with deferoxamine, heralding a new era for iron chelation.

The oral chelator deferasirox--a new perspective for patients with iron overload.

A Randomized phase II trial of deferasirox, a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload is presented.

Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.

An expert group of the International Committee on Oral Chelators (ICOC) has recommended a universally effective chelation combination protocol of oral deferiprone (L1) during the day (80-110 mg/kg

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.

The early use of deferoxamine in an amount proportional to the transfusional iron load reduces the body iron burden and helps protect against diabetes mellitus, cardiac disease, and early death in patients with thalassemia major.

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Deferasirox showed a plasma elimination half-life of 8-16 hours, supporting its once-daily administration, and was well tolerated and showed similar efficacy to DFO 40 mg/kg in terms of decreases in LIC.

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older, and found it to be a promising once-daily oral therapy for the treatment of transfusional iron overload.

Exjade (ICL 670): A new oral iron chelator.

The drug has been just approved by US FDA for use in iron-loading anaemias and is an ideal once-daily oral chelator, the effective dose of which is between 20 and 40 mg/kg.

Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major.

ICL670 (deferasirox) is an investigational, once-daily oral iron chelator which has been shown to effectively and selectively mobilize tissue iron in adults with transfusional hemosiderosis. The

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

The dose employed was too low to induce a net negative iron balance in this regularly transfused population of pediatric patients with transfusion-dependent beta-thalassemia major, and pharmacokinetic data support a once-daily dosing regimen based on body weight.